Even though there is no evidence of interactions between semaglutide and cannabis nor of reports of reduced efficacy, this is an area that requires monitoring
In the SUSTAIN 6 trial, over 3,297 patients with type 2 diabetes with established chronic kidney disease and/or cardiovascular disease underwent randomization to semaglutide or placebo and were followed for 2 years resulting in a 26% risk reduction in the combined endpoint of rate of cardiovascular disease, nonfatal myocardial infarction, or nonfatal stroke [47]
Bean, DJ, Monroe J, Liang YM, Borberg E, Senussi Y, Swank Z, et al
Targeting Hedgehoga cancer stem cell pathway
Dosage is introduced gradually to minimize side effects and support comfort